Pharvaris N.V. (NASDAQ:PHVS) Short Interest Down 42.9% in May

Pharvaris N.V. (NASDAQ:PHVS) saw a significant decrease in short interest in the month of May. As of May 15th, there was short interest totaling 600,645 shares, a decrease of 42.9% from the April 30th total of 1,051,478 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 463,899 shares, the short-interest ratio is currently 1.3 days.

Pharvaris Price Performance

Shares of NASDAQ PHVS traded down $0.08 during midday trading on Tuesday, reaching $29.02. The company’s stock had a trading volume of 143,389 shares, compared to its average volume of 357,013. Pharvaris has a 12-month low of $15.91 and a 12-month high of $33.33. The firm has a 50 day moving average price of $28.86 and a 200-day moving average price of $27.16. The stock has a market capitalization of $1.90 billion, a P/E ratio of -9.06 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, equities analysts predict that Pharvaris will post -3.25 EPS for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the subject of a number of research reports. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Wedbush lifted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $49.18.

Insider Buying and Selling

In other news, CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $29.22, for a total value of $66,972.24. Following the completion of the transaction, the chief executive officer directly owned 137,500 shares of the company’s stock, valued at approximately $4,017,750. This trade represents a 1.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Elisabeth Bjork sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $29.32, for a total value of $293,200.00. Following the completion of the transaction, the director directly owned 15,167 shares in the company, valued at $444,696.44. This represents a 39.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 209,948 shares of company stock valued at $6,268,141. Corporate insiders own 11.84% of the company’s stock.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds have recently made changes to their positions in PHVS. Wellington Management Group LLP bought a new position in Pharvaris during the third quarter valued at about $43,282,000. Paradigm Biocapital Advisors LP raised its position in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares during the period. Balyasny Asset Management L.P. purchased a new position in Pharvaris in the third quarter valued at about $15,613,000. Commodore Capital LP grew its position in shares of Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period. Finally, General Atlantic L.P. grew its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.